Naproxen. A new non-hormonal anti-inflammatory agent. Studies in rheumatoid arthritis.

Hill, H F; Hill, Alan; Mowat, A G; Ansell, B. M.; Mathews, John; Seifert, Martin; Gumpel, J M; Christie, George A.

doi:10.1136/ard.33.1.12

Cited by 32 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are reports associating hearing loss, tinnitus or vertigo with naproxen (Chapman 1982;Hill et al 1974;Wasner et al 1981), indomethacin (Pinals & Frank 1967;Wasneret al 1981), ibuprofen (OickSmith 1969Wasner et al 1981), fenoprofen (Diamond 1976; Wasner et al 1981), tolmetin (April et Drug Safety 9 (2) 1993Wasner et al 1981), benoxaprofen (Gum 1980;Wasner et al 1981), clopirac (Viara 1975), mefenamic acid (Miller 1985) and pirprofen (Davis et al 1979). …”

Section: Mechanisms Of Ototoxicitymentioning

confidence: 96%

Ototoxicity Associated with Salicylates

Brien

1993

Drug Safety

View full text Add to dashboard Cite

Aspirin, the prototype of the salicylates, is a ubiquitous agent. The availability of aspirin, other salicylates and nonsteroidal anti-inflammatory drugs (NSAIDs) as prescription and over-the-counter medications means there is a wealth of clinical experience with these agents. Among the documented adverse effects of aspirin is the potential for ototoxicity. Tinnitus and hearing loss, usually reversible, are associated with acute intoxication and long term administration of salicylates. A range of measured serum concentrations are reported as correlating with documented ototoxicity (19.6 to > 67 mg/dl). Most case reports are based on total serum salicylate concentrations whereas unbound serum salicylate concentrations appear to reflect more closely the risk of ototoxicity. The pathophysiology of toxicity may be related to biochemical and subsequent electrophysiological changes in the inner ear and eighth cranial nerve impulse transmission. Localised drug accumulation and vasoconstriction in auditory microvasculature may be mediated by the antiprostaglandin activity of these agents. Ototoxicity, although not life-threatening, may add to the morbidity of patients taking salicylates or NSAIDs in therapeutic and toxic doses.

show abstract

Section: Mechanisms Of Ototoxicitymentioning

confidence: 96%

Ototoxicity Associated with Salicylates

Brien

1993

Drug Safety

View full text Add to dashboard Cite

show abstract

“…Naproxen is an anti-inflammatory and analgesic agent which is widely used in rheumatoid arthritis with fewer reported side effects, particularly those of gastrointestinal intolerance, than aspirin or indomethacin (Kogstad, 1973;Hill et al, 1974). It has been suggested that naproxen is effective in the treatment of acute gout (Cuq, 1973;Willkens et al, 1975) and it was accordingly decided to compare the efficacy of this agent with that of phenylbutazone.…”

mentioning

confidence: 99%

Multicentre trial of naproxen and phenylbutazone in acute gout.

Sturge¹,

Scott²,

Hamilton³

et al. 1977

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

SUMMARY Naproxen 750 mg as a single dose followed by 250 mg three times daily has been compared with phenylbutazone 200 mg four times daily for 48 hours followed by 200 mg three times daily for the treatment of acute gout in an open study on 41 patients.The drugs were equally effective with few and relatively mild side effects. Naproxen is a useful alternative agent for the treatment of acute gout.

show abstract

“…Naproxen is an effective alternative to aspirin in the management of rheumatoid arthritis (Hill et al, 1974). While salicylates remain the drug of choice as the initial treatment of childhood arthritis (Ansell, 1975), in some patients they are either ineffective or not tolerated.…”

mentioning

confidence: 99%